Immunohistochemical features of the bone tissue of the lower extremities in patients with type 2 diabetes mellitus
https://doi.org/10.14341/DM12812
Abstract
Background: Diabetic neuroosteoarthropathy is a serious disabling complication of diabetes mellitus, which, in the absence of timely correct treatment, can lead to high amputations of the affected limb. At present, the reasons and mechanism of the development of Charcot’s foot are not completely clear. It is extremely important to determine the pathophysiological mechanisms of DNOAP formation and to search for reliable markers-predictors of this pathology.
Aim: To study the immunohistochemical characteristics of the bone tissue of the lower extremities in patients with diabetic neuroosteoarthropathy in comparison with patients with diabetes mellitus without this pathology.
Materials and methods: During the foot surgery, a bone fragment of the foot was harvested for immunohistochemical study of receptor markers for PINP, PIIINP, and RAGE in the group of patients with DNOAP compared with the control group.
Results: The study included 20 patients with type 2 diabetes mellitus and were divided into 2 groups: 10 patients with DNOAP made up group 1, 10 patients without DNOAP — group 2.
Patients in both groups were comparable in AGE, experience with type 2 diabetes, and glycemic control.
During the immunohistochemical study, a significant increase in the staining intensity of receptor markers for PINP, PIIINP, and AGE was recorded in the group of patients with DNOAP compared with the control group (p <0.05).
Conclusion: For the first time, an immunohistochemical study of markers of bone resorption and AGE was carried out in persons with DNOAP. The results obtained indicate impaired collagen formation and, as a consequence, impaired bone formation and bone resorption in patients with DNOAP: in group 1, a statistically significant increase in the expression of PINP, PIIINP, and RAGE was revealed.
About the Authors
A. Yu. TokmakovaRussian Federation
Alla Yu. Tokmakova - MD, PhD; eLibrary SPIN: 7479-7043.
Competing Interests:
no
E. A. Kogan
Russian Federation
Evgeniya A. Kogan - MD, PhD, Professor; eLibrary SPIN: 2709-2449
Competing Interests:
no
E. L. Zaitseva
Russian Federation
Ekaterina L. Zaitseva - MD, PhD; eLibrary SPIN: 1075-3022.
11 Dm.Ulyanova street, 117036 Moscow
Competing Interests:
no
S. A. Demura
Russian Federation
Sofia A. Demura - MD, PhD; eLibrary SPIN: 9220-4883
Competing Interests:
no
N. V. Zharkov
Russian Federation
Nikolay V. Zharkov - senior laboratory assistant; eLibrary SPIN: 8812-9731
Competing Interests:
no
M. M. Kalandiya
Russian Federation
Mariya M. Kalandiya - PhD student
Competing Interests:
no
G. R. Galstyan
Russian Federation
Gagik R. Galstyan - MD, PhD, Professor; eLibrary SPIN: 9815-7509
Competing Interests:
no
References
1. Frykberg RG, Belczyk R. Epidemiology of the Charcot Foot. Clinics in Podiatric Medicine and Surger. Elsevier BV; 2008 Jan;25(1):17–28. doi:10.1016/j.cpm.2007.10.001 V
2. Strotman PK, Reif TJ, Pinzur MS. Charcot Arthropathy of the Foot and Ankle. Foot & Ankle International. SAGE Publications; 2016 Oct 8;37(11):1255–63. doi:10.1177/1071100716674434
3. Mascarenhas J V., Jude EB. The Charcot Foot as a Complication of Diabetic Neuropathy. Curr Diab Rep. 2014;14(12):1-9. doi:10.1007/s11892-014-0561-6
4. Wautier JL, Schmidt AM. Protein glycation: A firm link to endothelial cell dysfunction. CircRes. 2004;95(3):233-238. doi:10.1161/01.RES.0000137876.28454.64
5. Saito M, Soshi S, Fujii K. Effect of hyper- and microgravity on collagen post-translational controls of MC3T3-E1 osteoblasts. JBoneMinerRes. 2003;18(9):1695-1705. doi:10.1359/jbmr.2003.18.9.1695
6. Biochemical markers of bone turnover: part I: biochemistry and variability. SeibelMJClinBiochemRev. 2005 Nov; 26(4):97-122.]
7. Kanazawa I. Interaction between bone and glucose metabolism. Endocr J. 2017;64(11):1043-1053. doi:10.1507/endocrj.EJ17-0323
8. Lee EJ, Park JH. Receptor for Advanced Glycation Endproducts (RAGE), Its Ligands, and Soluble RAGE: Potential Biomarkers for Diagnosis and Therapeutic Targets for Human Renal Diseases. Genomics Inform. 2013;11(4):224. doi:10.5808/gi.2013.11.4.224
9. McCabe LR. Understanding the pathology and mechanisms of type I diabetic bone loss. Journal of Cellular Biochemistry 2007 102 1343–1357. doi:10.1002/jcb.21573
10. Sanguineti R, Puddu A, Mach F, Montecucco F, Viviani GL. Advanced glycation end products play adverse proinflammatory activities in osteoporosis. MediatorsofInflammation 2014 2014 975872. doi:10.1155/2014/975872
11. Farlay D, Armas LA, Gineyts E, Akhter MP, Recker RR, Boivin G. Nonenzymatic glycation and degree of mineralization are higher in bone from fractured patients with type 1 diabetes mellitus. JournalofBoneandMineralResearch 2016 31 190–195. doi:10.1002/jbmr.2607
12. Volk SW, Shah SR, Cohen AJ, et al. Type III collagen regulates osteoblastogenesis and the quantity of trabecular bone. CalcifTissueInt. 2014;94(6):621-631. doi:10.1007/s00223-014-9843-x
Supplementary files
|
1. Figure 1. Histological picture of bone tissue in diabetic neuroosteoarthropathy: A - fields of bone osteolysis with ingrowth into foci of destruction of granulation tissue with hyalinosis of the walls of microvessels and swelling of the endothelium. Granulation tissue contains pronounced inflammatory infiltrates and sclerotic changes. In the foci of osteolysis, a large number of osteoclasts are found; B - bone tissue without pathological changes in patients with diabetes mellitus (control). | |
Subject | ||
Type | Исследовательские инструменты | |
View
(252KB)
|
Indexing metadata ▾ |
|
2. Figure 2. Immunohistochemical picture of PINP expression in bone tissue: A - high expression of the marker in fibroblastic elements and cells of the inflammatory infiltrate of granulation tissue, as well as in osteoclasts in patients with diabetic neuroosteoarthropathy; B - weak expression of the marker in individual osteoblasts and bone marrow cells in control patients. | |
Subject | ||
Type | Исследовательские инструменты | |
View
(214KB)
|
Indexing metadata ▾ |
|
3. Figure 3. Immunohistochemical picture of PIIINP expression in bone tissue: A - high expression of the marker in fibroblastic elements and cells of the inflammatory infiltrate of granulation tissue, as well as in osteoclasts in patients with diabetic neuroosteoarthropathy; B - weak expression of the marker in individual osteoblasts and bone marrow cells in control patients. | |
Subject | ||
Type | Исследовательские инструменты | |
View
(252KB)
|
Indexing metadata ▾ |
|
4. Figure 4. Immunohistochemical picture of expression of AGE receptors in bone tissue. A - moderate expression of the marker in fibroblastic elements and cells of the inflammatory infiltrate of granulation tissue, as well as in osteoclasts in patients with diabetic neuroosteoarthropathy; B - weak expression of the marker in individual osteoblasts and bone marrow cells in control patients. Figure 5. Immunohistochemical characterization of PINP, PIIINP and AGE in bone biopsies with diabetic neuroosteoarthropathy (Charcot's foot) and without it (control). | |
Subject | ||
Type | Исследовательские инструменты | |
View
(248KB)
|
Indexing metadata ▾ |
Review
For citations:
Tokmakova A.Yu., Kogan E.A., Zaitseva E.L., Demura S.A., Zharkov N.V., Kalandiya M.M., Galstyan G.R. Immunohistochemical features of the bone tissue of the lower extremities in patients with type 2 diabetes mellitus. Diabetes mellitus. 2021;24(5):448-455. (In Russ.) https://doi.org/10.14341/DM12812

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).